E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 16,563.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 22,162 shares of the biotechnology company’s stock after acquiring an additional 22,029 shares during the quarter. Biogen comprises 1.2% of E Fund Management Hong Kong Co. Ltd.’s portfolio, making the stock its 18th largest holding. E Fund Management Hong Kong Co. Ltd.’s holdings in Biogen were worth $5,006,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the stock. Probity Advisors Inc. lifted its stake in shares of Biogen by 3.6% in the 3rd quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 41 shares during the period. Forum Financial Management LP boosted its position in shares of Biogen by 2.4% during the third quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 46 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Biogen by 3.5% during the third quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 48 shares during the last quarter. Wedbush Securities Inc. boosted its stake in shares of Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company’s stock worth $251,000 after buying an additional 56 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after purchasing an additional 65 shares during the period. Institutional investors own 87.93% of the company’s stock.
Biogen News Roundup
Investors following BIIB have been watching these news items:
- Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with ?-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
- Positive Sentiment: A new research collaboration with TRIMTECH will explore protein-degrader approaches for neurodegenerative diseases, offering possible longer-term pipeline potential, though it remains early-stage research. Article
- Negative Sentiment: A report of elevated buying in BIIB put options points to some investor hedging or bearish positioning, though the headline provides no details on the size or significance of the activity. Article
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. UBS Group boosted their price objective on shares of Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Barclays boosted their price objective on Biogen from $200.00 to $230.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 28th. Guggenheim lifted their target price on Biogen from $280.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. HSBC lifted their target price on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Finally, Robert W. Baird increased their price objective on shares of Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Biogen presently has an average rating of “Moderate Buy” and a consensus price target of $255.45.
Get Our Latest Research Report on Biogen
Biogen Stock Up 1.0%
Shares of NASDAQ:BIIB opened at $249.59 on Friday. Biogen Inc. has a 52-week low of $160.36 and a 52-week high of $261.00. The business’s 50 day moving average is $236.83 and its 200 day moving average is $206.86. The stock has a market cap of $36.89 billion, a P/E ratio of 106.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.81 EPS. Sell-side analysts predict that Biogen Inc. will post 12.46 EPS for the current year.
About Biogen
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Further Reading
- Five stocks we like better than Biogen
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
